BioCentury | Jul 14, 2014
Financial News

Synchroneuron Inc completes venture financing

Synchroneuron Inc ., Waltham, Mass. Business: Neurology Date completed: 2014-07-02 Type: Venture financing Raised: Not disclosed Investor: Morningside Technology Ventures Note: The company raised an undisclosed amount in a tranched $20 million series B round....
BioCentury | Jul 3, 2014
Financial News

Synchroneuron secures $20 million in series B

...Movement disorder company Synchroneuron Inc. (Waltham, Mass.) secured $20 million in a tranched series B round led...
...to treat Tourette's syndrome and post-traumatic stress disorder (PTSD), but declined to disclose a timeline. Synchroneuron...
BioCentury | Mar 3, 2014
Clinical News

Acamprosate: Phase II started

...to evaluate oral SNC-102 once or twice daily for 4 weeks in about 90 patients. Synchroneuron Inc....
BioCentury | Feb 13, 2012
Financial News

Synchroneuron completes venture financing

Synchroneuron Inc. , Waltham, Mass. Business: Neurology Date completed: 2/6/12 Type: Venture financing Raised: $6 million Investor: Morningside Group WIR Staff Neurology...
BioCentury | Feb 8, 2012
Financial News

Newco Synchroneuron raises $6 million

...Movement disorder newco Synchroneuron Inc. (Waltham, Mass.) raised $6 million in a series A round led by...
...Waltham, Mass.) raised $6 million in a series A round led by Morningside Technology Ventures. Synchroneuron's...
Items per page:
1 - 5 of 5
BioCentury | Jul 14, 2014
Financial News

Synchroneuron Inc completes venture financing

Synchroneuron Inc ., Waltham, Mass. Business: Neurology Date completed: 2014-07-02 Type: Venture financing Raised: Not disclosed Investor: Morningside Technology Ventures Note: The company raised an undisclosed amount in a tranched $20 million series B round....
BioCentury | Jul 3, 2014
Financial News

Synchroneuron secures $20 million in series B

...Movement disorder company Synchroneuron Inc. (Waltham, Mass.) secured $20 million in a tranched series B round led...
...to treat Tourette's syndrome and post-traumatic stress disorder (PTSD), but declined to disclose a timeline. Synchroneuron...
BioCentury | Mar 3, 2014
Clinical News

Acamprosate: Phase II started

...to evaluate oral SNC-102 once or twice daily for 4 weeks in about 90 patients. Synchroneuron Inc....
BioCentury | Feb 13, 2012
Financial News

Synchroneuron completes venture financing

Synchroneuron Inc. , Waltham, Mass. Business: Neurology Date completed: 2/6/12 Type: Venture financing Raised: $6 million Investor: Morningside Group WIR Staff Neurology...
BioCentury | Feb 8, 2012
Financial News

Newco Synchroneuron raises $6 million

...Movement disorder newco Synchroneuron Inc. (Waltham, Mass.) raised $6 million in a series A round led by...
...Waltham, Mass.) raised $6 million in a series A round led by Morningside Technology Ventures. Synchroneuron's...
Items per page:
1 - 5 of 5